Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 16th Preview)
-
FDA greenlights ctDNA MRD-guided adjuvant immunotherapy in bladder cancer
The FDA approved Genentech’s Tecentriq (atezolizumab) and Tecentriq Hybreza (subcutaneous atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for patients with muscle-invasive bladder cancer who have circulating tumor DNA after cystectomy, as determined by Natera’s Signatera CDx. The approval marks the first FDA authorization of a ctDNA MRD-guided therapy in bladder cancer, alongside a simultaneous FDA authorization for Signatera as the companion diagnostic. Patients with a positive MRD result may receive adjuvant immunotherapy, while those with negative results may avoid treatment. FDA reviewed results from the Phase 3 IMvigor011 trial, in which 250 ctDNA-positive patients were randomized to Tecentriq or placebo. Disease-free survival was nearly doubled with Tecentriq (9.9 months vs 4.8 months), and median overall survival also improved (32.8 vs 21.1 months).
-
Phase 3 readout for telitacicept in IgA nephropathy
RemeGen’s telitacicept delivered a strong interim efficacy signal in a prespecified Phase 3 analysis in high-risk IgA nephropathy, according to results presented at NEJM.org and associated meeting presentations. In the trial of 318 adults with biopsy-proven IgA nephropathy and persistent proteinuria despite supportive care, telitacicept produced a substantially larger reduction in urinary protein-to-creatinine measures at 39 weeks than placebo. The geometric mean ratio of 24-hour protein-to-creatinine fell 58.9% with telitacicept versus 8.8% with placebo. Safety events were more frequent with telitacicept (89.3% vs 78.6%), though serious adverse events were less common than with placebo (2.5% vs 8.2%). No unexpected safety findings were reported, and estimated glomerular filtration rate changes favored telitacicept directionally at interim follow-up.
-
New gene therapy targeting liver for hemophilia A
Researchers reported efficacy improvements with two engineered AAV8 vectors—HMR-001 and its codon-optimized counterpart HMR-001z—in a hemophilia A gene therapy study focused on restoring hemostasis. The work describes bioengineered vector performance aimed at addressing limitations seen with earlier gene delivery strategies for factor VIII replacement. (Hemophilia A is caused by factor VIII deficiency.) The update underscores ongoing optimization of AAV liver-targeted delivery for durability and effectiveness, as gene therapy developers continue to refine vector design to improve expression and safety profiles.
-
Aardvark hits full FDA clinical hold after cardiovascular signal
FDA placed Aardvark Therapeutics’ Prader-Willi syndrome program under a full clinical hold, halting further testing of ARD-101 and related studies following a cardiovascular safety issue observed in a healthy volunteer. Aardvark had earlier paused parts of its program voluntarily after the signal, then expanded the pause across ARD-101 and an ARD-201 combination approach. With the formal hold now in place, the company said it will unblind trial data to support regulator review of safety and efficacy. The company reported it had dosed 68 patients in the randomized Phase 3 trial and 19 in an open-label extension. The hold also adds financing pressure as cash runway is projected to reach mid-2027, tightening timelines for any resumption path agreed with FDA.
-
Gene therapy safety case raises AAV integration scrutiny
A CHOP-led team presented evidence of a brain tumor linked to rare adeno-associated virus (AAV) integration, highlighting a potential long-term risk to the AAV gene therapy field. The case, presented at ASGCT and published in the New England Journal of Medicine, involved a 5-year-old boy with severe MPS I deficiency who later developed a PLAG1-driven neuroepithelial tumor after intracisternal magna delivery of an AAV9 vector carrying IDUA. RNA sequencing found a fusion consistent with AAV9 cassette integration to PLAG1. Investigators reported successful tumor removal and no signs of growth eight months post-surgery, while the presentation framed the episode as a signal to strengthen long-term monitoring and deepen understanding of integration-related events.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.